TYMS and DPYD polymorphisms in a Turkish population

European Journal of Clinical Pharmacology

Volumn 61, Issue 12, 2005, Pages 881-885

  Suzen H S ^a   Yuce N ^a   Guvenc G ^a   Duydu, Y ^a   Erke, T ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b BAYINDIR HOSPITAL   (Turkey)

Author keywords

DPYD; Polymorphism; Turkish; TYMS

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; CHINESE; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; EGYPT; ENHANCER REGION; EXON; FEMALE; FINLAND; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; HUNGARY; IRELAND; JAPANESE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOMES RESEARCH; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; TAIWAN; TURKEY (REPUBLIC);

ADULT; AGED; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENETICS, POPULATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE; TURKEY;

EID: 29144493773     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0054-2     Document Type: Article

References (38)

1. Kawakami K (2004) Thymidylate synthase gene in pharmacogenetics. Curr Pharmacogenomics 2:137-147
2. Horie N, Aiba H, Ogura K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal region of the human gene for thymidylate synthase. Cell Struct Func 20:191-197
3. Marsh S, Collie-Duguid ESR, Li T, Liu X, McLeod HL (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310-312
4. Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum Mut 16:528-533
5. Pullakart ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65-70
6. Villafranca E, Okruzhnov Y, Dominguez MA et al (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancers. J Clin Oncol 19:1779-1786
7. Diasio RB, Johnson MR (2000) The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-FU. Pharmacology 61:199-203
8. McMurrough J, McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41:425-427
9. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G. (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253
10. Wei X, Elizondo G, Sapone A, McLeod HL, Raunino H, Fernandoz-Salguero P, Gonzalez FJ (1998) Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51:391-400
11. van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939-950
12. Raida M, Schwabe W, Hausler P, van Kuilenburg ABP, van Gennip AH, Behnke D, Hoffken D (2001) Prevalence of common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with contols. Clin Cancer Res 7: 2832-2839
13. van Kuilenburg ABP, Vreken P, Abeling NGGM et al (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104:1-9
14. van Kuilenburg ABP, Meinsma JR, Zoetekouw L, van Gennip AH (2002) High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12:555-558
15. Johnson MR, Hageboutros A, Wang K, Hish L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient following treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006-2011
16. Johnson MR, Diasio R (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151-157
17. Morrison GB, Bastianm A, Dela-Rosa T, Diasio RB, Takimoto CH (1997) Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe advers reactions to 5-fluorouracil based chemotherapy. Oncol Nursing Forum 24:83-88
18. van Kuilenburg ABP, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149-1153
19. Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107:155-176
20. Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104-111
21. Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90:8-11
22. Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J (2005) Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54:171-196
23. Sekine I, Saijo N (2001) Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 12:1515-1525
24. Smith NF, Figg WD, Sparreboom A (2004) Recent advances in pharmacogenetic approaches to anticancer drug development. Drug Dev Res 62:233-253
25. Yamayoshi Y, Iida E, Tanigawara Y (2005) Cancer pharmacogenomics : international trends. Int J Clin Oncol 10:5-13
26. Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7:201-204
27. Wei X, McLeod HL, NcMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouraci toxicity. J Clin Invest 98:610-615
28. Adleef V, Hitre E, Köves I, Orosz Z, Hajnal A, Kralovanszky J (2004) Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients. Int J Cancer 108:852-856
29. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Tajima K (2003) Associations between polymorphisms in the thymidylate synthase and serine hydroxymethylytransferase genes and susceptibility to malignant lymphoma. Haematologica 88:159-166
30. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW (2002) Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Genet 111:299-302
31. Luo HR, Lü XM, Yao YG, Horie N, Takeishi K, Jorde LB, Zhang YP (2002) Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 40:41-51
32. Brown KS, Kluijtmans LAJ, Young IS, McNulty H, Mitchell LE et al (2004) The thymidylate synthase tandem repeat polymorphism is not associated with homocysteine concentrations in healthy young subjects. Hum Genet 114:182-185
33. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S (2002) Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 20:333-339
34. Nauck M, Gierens H, Marz W, Wieland H (2001) Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 34:103-105
35. Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF (2004) Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 54:445-451
36. Yamaguchi K, Arai Y, Kanda Y, Akagi K (2001) Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Can Res 92:337-342
37. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MSE, Mizugaki M (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596-603
38. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg ABP, van Gennip AH, Mcleod HL (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46:151-156